Resources


April 27, 2020

iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™

- Company Expands Involvement in the Manufacturing USA® Network, Joining the National Institute for Innovation in Manufacturing Biopharmaceuticals -  

Continue Reading

April 9, 2020

iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute

- The Nonprofit Will Help Lead Pre-Clinical Development and Clinical Trial Oversight - NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and ...

Continue Reading

March 27, 2020

iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into a second Statement of Work under its Master Joint Development Agreement (the “MJDA”) with AzarGen ...

Continue Reading

March 26, 2020

iBio Announces Advancement of COVID-19 Vaccine Program

Preclinical Immunization Studies at Texas A&M University NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced ...

Continue Reading

March 20, 2020

iBio Joins the Alliance for Biosecurity

NEW YORK, March 20, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that it has joined the Alliance for Biosecurity, a ...

Continue Reading
1 2 3